Kuno van der Post Ph.D
OmniComm Systems, Inc.
FORT LAUDERDALE, FL--(Marketwire - Oct 6, 2011) - OmniComm Systems, Inc., one of the fastest growing companies in the Electronic Data Capture (EDC) marketplace, today announced that its TrialMaster suite of applications has been licensed by McDougall Scientific, Ltd. (McDougall) to bolster its service offering to its customers. McDougall chose OmniComm, after evaluating several of the other leading EDC vendors, for their functionally rich offering, flexible business model, first-rate technology training program and their commitment to excellent customer service.
"The McDougall philosophy has not changed in the last 28 years -- provide cost-effective, personalized, quality services and products -- on time and on budget. OmniComm shares that philosophy and that is very important to us. Within the OmniComm training program McDougall has quickly transitioned to building best-in-class EDC implementations that leverage the OmniComm expertise as well as the deep experience of our statisticians and data managers. There is even a great interface for our existing IVRS technology. We are looking forward to expanding the partnership with OmniComm and providing that personalized McDougall experience in EDC to more clients," said Janet McDougall, President of McDougall.
McDougall also joins the OmniComm CRO Preferred Program, bringing the program's membership count to close to 50 organizations. With this partnership, McDougall will be able to build their own trials and offer the TrialMaster® Electronic Data Capture (EDC) solution to its clinical research customers.
"McDougall offers high quality, full-service statistical consulting and data management services and has extensive experience working in a fast-paced, regulated environment," said Stephen Johnson, President and COO of OmniComm. "The addition of TrialMaster to their service offering aligns perfectly with their goal of offering best practices to create high quality deliverables on time and on budget. We are delighted that McDougall has chosen OmniComm's products and services and look forward to their participation in our CRO Preferred Program."
The OmniComm CRO Preferred Program offers its CRO members exclusive benefits, such as a dedicated, hosted environment, sales and marketing support and training, all at a fixed price for predictability and dependability. This turnkey EDC solution allows its CRO partners to pass along the benefits of a world-class EDC solution to its customers to streamline their clinical research.
About OmniComm OmniComm Systems, Inc. (www.omnicomm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's pricing model is easily understood and allows companies ranging from small, to large, to maximize their clinical research investments. OmniComm Systems, Inc. has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey and the United Kingdom, as well as sales offices throughout the U.S. and Europe.
About McDougall Scientific, Ltd. McDougall Scientific, Ltd. (www.mcdougallscientific.com) is a pharmaceutical contract research organization specializing in high quality, full-service statistics, clinical data management services and interactive voice recognition systems. Since its founding in 1984 as a statistical consulting firm to the research community, McDougall has become a trusted name in statistical consulting and data management services throughout the pharmaceutical, biotech and medical device industries.
Safe Harbor Disclaimer Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.